Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7692009 | 0.98 | HTT (0.58) | HTTTDP1KMT2AL3MBTL1MEN1 | |
| SCHEMBL8396793 | 0.98 | HTT (0.58) | HTTTDP1KMT2AL3MBTL1MEN1 | |
| SCHEMBL8394588 | 0.98 | HTT (0.58) | HTTTDP1KMT2AL3MBTL1MEN1 | |
| SCHEMBL8397091 | 0.98 | HTT (0.62) | HTTTDP1KMT2AL3MBTL1MEN1 | |
| SCHEMBL8393260 | 0.96 | HTT (0.60) | HTTTDP1KMT2AL3MBTL1MEN1 | |
| SCHEMBL8391321 | 0.96 | HTT (0.60) | HTTTDP1KMT2AL3MBTL1MEN1 | |
| SCHEMBL8395941 | 0.96 | HTT (0.60) | HTTTDP1KMT2AL3MBTL1MEN1 | |
| SCHEMBL1681188 | 0.94 | HTT (0.67) | HTTTDP1KMT2AL3MBTL1MEN1 | |
| SCHEMBL4732560 | 0.92 | HTT (0.69) | HTTTDP1KMT2AL3MBTL1MEN1 | |
| SCHEMBL21902726 | 0.89 | HTT (0.52) | HTTTDP1KMT2AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-8604055-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-12-10 | — | — | US | disclosed |
| EP-1846366-B1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7915420-B2 | Aryl piperidine amides | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080009521-A1 | Aryl Piperidine Amides | HUANG CHARLES Q | 2008-01-10 | — | — | US | disclosed |
| EP-1846366-A1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-7276610-B2 | Aryl piperidine amides | JANSSEN PHARACEUTICA, NV (BE) | 2007-10-02 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| WO-2006080477-A1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2006-08-03 | — | — | WO | disclosed |
| EP-1660472-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021525-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-10 | — | — | WO | disclosed |
| US-20050049239-A1 | Aryl piperidine amides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
| WO-2005019200-A2 | ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, DBI | HTT 1081/4885TDP1 2110/4885KMT2A 1742/4885 |
| US-20080009521-A1 | Aryl Piperidine Amides | BDNF, NTRK2, OPRL1 | HTT 207/4885TDP1 1751/4885KMT2A 472/4885 |
| US-20050049239-A1 | Aryl piperidine amides | BDNF, NTRK2, OPRL1 | HTT 207/4885TDP1 1751/4885KMT2A 472/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | HTT 1081/4885TDP1 2110/4885KMT2A 1742/4885 |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | SLC38A7, SLC7A1, SLC6A7 | HTT 408/4885TDP1 4604/4885KMT2A 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.